Our experts will discuss the details of Invitae's sponsored, no-charge testing programs. They will outline the structure and benefits of the programs and discuss how they are designed to increase access to genetic testing. We will also dive into Invitae's de-identified data sharing policies and share how we protect your patients' personal information. Finally, we will discuss the benefits of the sponsored testing programs. The presentation will be approximately 30 minutes followed by 30 minutes of Q&A.
It’s challenging to do exome sequencing well, but with the right combination of clinical expertise and leading-edge technology, it’s possible to achieve comprehensive, reproducible, and accurate results.
But that’s not enough, as changes, such as the publication of new gene-disease associations or the development of new clinical findings, often occur. To ensure you always have the most recent results—without any extra work on your part—we’re providing continual, automatic re-analysis.
This webinar will help you:
The utility of RNA analysis to uncover etiologies of hereditary disease is an active area of investigation. While there are studies showing some benefits of RNA analysis for variant detection and classification, there are important complexities to consider when implementing this technology into clinical laboratory practices.
This webinar will help genetic counselors and healthcare providers understand RNA analysis in variant detection and variant classification, its benefits, and potential limitations.
At Invitae, we understand that you always want the most accurate, up-to-date information about your patient’s exome—without extra work required on your part. Every six months (for a period of three years from the exome report date), Invitae now automatically runs an expert, case-level reanalysis of your patient’s exome.
How are we able to do this? Invitae recently integrated Moon, an intelligent software engine into our exome platform. Moon allows for more efficient, comprehensive, and personalized exome sequencing.